US Broker Ratings

argenx SE (ARGX) Stock Analysis: Biotechnology Giant with 25.90% Upside Potential

Investors with an eye on the biotechnology sector might find argenx SE (NASDAQ: ARGX) a compelling opportunity, particularly given its significant market cap of $50.87 billion. Operating primarily in the..

Sanofi (SNY) Stock Analysis: A 25% Potential Upside with Strong Dividend Yield

Sanofi (SNY), a global healthcare leader headquartered in Paris, France, is making waves in the pharmaceutical industry with its robust portfolio of therapeutic solutions and vaccines. With a market capitalization..

Teva Pharmaceutical Industries (TEVA) Stock Analysis: Uncovering a 10% Upside Potential for Investors

Teva Pharmaceutical Industries Limited (NYSE: TEVA), a prominent player in the global healthcare sector, continues to capture the attention of investors seeking growth in the drug manufacturing industry. With a..

Pfizer, Inc. (PFE) Stock Analysis: Navigating a 6.24% Dividend Yield Amidst Market Complexity

Pfizer Inc. (NYSE: PFE), a stalwart in the healthcare sector, continues to captivate investors with its robust portfolio of biopharmaceutical products and a compelling dividend yield of 6.24%. This New..

Johnson & Johnson (JNJ) Stock Analysis: Navigating a 9.1% Revenue Growth in Healthcare

Johnson & Johnson (NYSE: JNJ), a stalwart in the healthcare sector, is navigating a complex landscape with a market cap standing tall at $586.69 billion. As the company continues to..

STERIS plc (STE) Stock Analysis: Attractive Growth Potential with 13.25% Upside

STERIS plc (NYSE: STE) is a prominent player in the medical devices industry, renowned for its infection prevention products and services. Operating globally, STERIS is structured into three segments: Healthcare,..

DexCom, Inc. (DXCM) Stock Analysis: A Compelling 22% Upside Amidst Growing Healthcare Demand

Investors in the healthcare sector might find DexCom, Inc. (DXCM) an intriguing prospect, especially considering its pivotal role in the medical devices industry. With a market capitalization of $27.31 billion,..

Novartis AG (NVS) Stock Analysis: Navigating Growth with a 2.93% Dividend Yield in the Healthcare Sector

For individual investors seeking opportunities in the healthcare sector, Novartis AG (NYSE: NVS) presents an intriguing case. As a Swiss pharmaceutical giant, Novartis commands a market capitalization of $315.28 billion,..

Danaher Corporation (DHR) Stock Analysis: Exploring a 24.62% Potential Upside and Strong Buy Ratings

Danaher Corporation (NYSE: DHR) stands as a formidable entity within the Healthcare sector, specifically in the Diagnostics & Research industry. With a market capitalization of $150.27 billion, Danaher is a..

HCA Healthcare, Inc. (HCA) Stock Analysis: Evaluating Growth Potential and Market Position

Investors seeking a robust presence in the healthcare sector should consider HCA Healthcare, Inc. (NYSE: HCA), a titan in the medical care facilities industry with a considerable market cap of..

Medtronic plc (MDT) Stock Analysis: Riding the Upside Wave with 12.57% Potential Growth

Medtronic plc (MDT), headquartered in Galway, Ireland, stands as a formidable player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $127.61 billion, Medtronic..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Biotech Innovator with Over 105% Potential Upside

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a burgeoning player in the biotechnology sector, is capturing the attention of investors with its promising pipeline of cancer therapies and a remarkable potential upside..

MBX Biosciences, Inc. (MBX) Stock Analysis: A Biotech with a 60.79% Potential Upside

MBX Biosciences, Inc. (MBX) is making waves in the biotechnology sector with its focus on precision peptide therapies aimed at treating endocrine and metabolic disorders. With a market cap of..

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Pioneer with 31.43% Upside Potential

Septerna, Inc. (SEPN), a burgeoning name in the biotechnology sector, has captured investor attention with its remarkable revenue growth and potential upside. As a clinical-stage biotech company, Septerna is pioneering..

Abivax SA (ABVX) Stock Analysis: A 22.77% Potential Upside and Strong Buy Consensus

Abivax SA (ABVX), a French biotechnology powerhouse, is drawing significant investor attention with its promising potential upside of 22.77% as indicated by analyst targets. Operating at the cutting edge of..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Biotechnology Player with a 60% Upside Potential

As a relatively new entrant in the healthcare sector, Fortrea Holdings Inc. (NASDAQ: FTRE) is making waves in the biotechnology industry. Incorporated in 2023 and headquartered in Durham, North Carolina,..

PureTech Health plc (PRTC) Stock Analysis: Unveiling a 542.7% Revenue Growth Potential

PureTech Health plc (PRTC), a biotechnology firm based in Boston, Massachusetts, is quietly making waves in the healthcare sector. With a focus on developing and commercializing innovative biotech and pharmaceutical..

AtaiBeckley Inc. (ATAI) Stock Analysis: Unveiling a 247.89% Potential Upside in Revolutionary Mental Health Treatments

For investors with an eye on the healthcare sector, AtaiBeckley Inc. (NASDAQ: ATAI) offers a compelling case of innovation in mental health treatment, coupled with a striking potential upside of..

Neuropace, Inc. (NPCE) Stock Analysis: A 34% Potential Upside Sparks Investor Interest

Neuropace, Inc. (NASDAQ: NPCE), a pioneering player in the healthcare sector, is drawing significant attention from investors. With its focus on medical devices, specifically targeting drug-resistant focal epilepsy through its..

Humacyte, Inc. (HUMA)

⚠️ No article content returned.

..
Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds